A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of ASA404 in Adult Cancer Patients With Impaired Hepatic Function and With Normal Hepatic Function.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2012
At a glance
- Drugs Vadimezan (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 05 May 2011 Planned End Date changed from 1 Apr 2011 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 05 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Jan 2011 New trial record